GlassScriptPhysician profile
Gustavo Gomez
NPI 1699031088
$1,454.25
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2020: $243 · 2021: $583 · 2022: $283.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $252.77 | 2019-2021 | |
| Novo Nordisk INC | $242.33 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $221.57 | 2019-2021 | |
| Abbvie INC. | $158.78 | 2021-2022 | |
| Lilly USA, LLC | $108.50 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.05 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $66.27 | 2022 | |
| Pfizer INC. | $53.47 | 2019-2021 | |
| Astellas Pharma US INC | $47.25 | 2019-2020 | |
| Dexcom, INC. | $41.08 | 2022 | |
| Glaxosmithkline, LLC. | $39.75 | 2019-2021 | |
| Shire North American Group INC | $32.43 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $22.30 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.75 | 2022 | |
| Allergan, INC. | $18.70 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $17.87 | 2020 | |
| Evoke Pharma, INC. | $14.92 | 2021 | |
| Supernus Pharmaceuticals, INC. | $12.08 | 2022 | |
| Janssen Pharmaceuticals, INC | $11.38 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gustavo Gomez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.